Approvals for Lotus Pharma's generics in the Philippines

2 March 2022

Taiwanese generics and biosimilar drugmaker Lotus Pharmaceutical (TWSE: 1795) has received approval for its abbreviated new drug application (ANDA) in the Philippines for its generic versions of Bristol Myers Squibb’s (NYSE: BMY) Revlimid (lenalidomide) and AstraZeneca’s (LSE: AZN) lung cancer drug Iressa (gefitinib).

A treatment for multiple myeloma (MM), lenalidomide is the first approved Revlimid generic in the Philippines. As disclosed by the originator, the total sales of Revlimid globally were $12.8 billion in 2021. Lotus believes that the market potential of lenalidomide in Philippines is around $10 million.

The company expects the launch of the two drugs will help expedite its expansion in Southeast Asia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK